Show simple item record

dc.contributor.authorSproviero, W
dc.contributor.authorShatunov, A
dc.contributor.authorStahl, D
dc.contributor.authorShoai, M
dc.contributor.authorvan Rheenen, W
dc.contributor.authorJones, AR
dc.contributor.authorAl-Sarraj, S
dc.contributor.authorAndersen, PM
dc.contributor.authorBonini, NM
dc.contributor.authorConforti, FL
dc.contributor.authorVan Damme, P
dc.contributor.authorDaoud, H
dc.contributor.authorAmador, MDM
dc.contributor.authorFogh, I
dc.contributor.authorForzan, M
dc.contributor.authorGaastra, B
dc.contributor.authorGellera, C
dc.contributor.authorGitler, AD
dc.contributor.authorHardy, J
dc.contributor.authorFratta, P
dc.contributor.authorLa Bella, V
dc.contributor.authorLe Ber, I
dc.contributor.authorVan Langenhove, T
dc.contributor.authorLattante, S
dc.contributor.authorLee, Y-C
dc.contributor.authorMalaspina, A
dc.contributor.authorMeininger, V
dc.contributor.authorMillecamps, S
dc.contributor.authorOrrell, R
dc.contributor.authorRademakers, R
dc.contributor.authorRobberecht, W
dc.contributor.authorRouleau, G
dc.contributor.authorRoss, OA
dc.contributor.authorSalachas, F
dc.contributor.authorSidle, K
dc.contributor.authorSmith, BN
dc.contributor.authorSoong, B-W
dc.contributor.authorSoraru, G
dc.contributor.authorStevanin, G
dc.contributor.authorKabashi, E
dc.contributor.authorTroakes, C
dc.contributor.authorvan Broeckhoven, C
dc.contributor.authorVeldink, JH
dc.contributor.authorvan den Berg, LH
dc.contributor.authorShaw, CE
dc.contributor.authorPowell, JF
dc.contributor.authorAl-Chalabi, A
dc.date.accessioned2019-02-22T11:49:49Z
dc.date.available2016-11-16
dc.date.available2019-02-22T11:49:49Z
dc.date.issued2016-11-24
dc.identifier.citationSproviero, W., et al. (2017). "ATXN2 trinucleotide repeat length correlates with risk of ALS." Neurobiology of Aging 51: 178.e171-178.e179.en_US
dc.identifier.issn0197-4580
dc.identifier.otherARTN 178.e1
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/55500
dc.description.abstractWe investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37–3.94]; p = 6 × 10−18), with an exponential relationship between repeat length and ALS risk for alleles of 29–32 repeats (R2 = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.en_US
dc.description.sponsorshipThis work was supported by the EU Joint Programme for Neurodegenerative Disease Research projects SOPHIA, STRENGTH, and NETCALS. Christopher E. Shaw, Ammar Al-Chalabi, and Daniel Stahl receive salary support from the National Institute for Health Research Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London. Philip Van Damme holds a senior clinical investigatorship of FWO-Flanders and is supported by the Belgian ALS ligue. William Sproviero, Richard Orrell, John Hardy, and Maryam Shoai are funded by the MND Association.en_US
dc.language.isoenen_US
dc.publisherElsevier/Science Directen_US
dc.relation.ispartofNEUROBIOLOGY OF AGING
dc.rightsCreative Commons Attribution License
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectATXN2en_US
dc.subjectSCA2en_US
dc.subjectALSen_US
dc.subjectCAGen_US
dc.subjectExpansionen_US
dc.subjectIntermediate expansionen_US
dc.subjectTrinucleotide repeaten_US
dc.subjectAmyotrophic lateral sclerosisen_US
dc.subjectAge of onseten_US
dc.subjectRisken_US
dc.subjectExponential risken_US
dc.subjectTripleten_US
dc.titleATXN2 trinucleotide repeat length correlates with risk of ALSen_US
dc.typeArticleen_US
dc.rights.holder2016 The Author(s).
dc.identifier.doi10.1016/j.neurobiolaging.2016.11.010
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000397168600022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNo embargoen_US
pubs.publication-statusPublisheden_US
pubs.volume51en_US
dcterms.dateAccepted2016-11-16
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution License
Except where otherwise noted, this item's license is described as Creative Commons Attribution License